Member Info for BOJO2020

Well SNG have a long and difficult journey but I think the BOD are doing the best possible considering. Cant see a big pharma stepping in unless SNG cross many of the hurdles on its own first.

DNL got FDA approval but they didn't gain. Just goes to show that investing takes patience lol.

SCLP held firm but the AGM may change that in a few weeks for better or worse.

Imm, well let us pray!

https://www.proactiveinvestors.co.uk/companies/news/930315/immupharma-reports-reduced-losses-eyes-further-lupuzor-progress-930315.html

We are only supposed to invest what we can afford to lose. Maybe some have over committed themselves...

This is how people are going to lose money. Jump out and accept losses and then jump back in at a premium. Each to their own as someone once said.

But we need to remember the science. If you don't understand the science then you don't understand the opportunity.

ATB.

Really fantastic news. Well done all PI. Nice to have a company that delivers in my portfolio.

Following todays positive and interesting developments, if you have questions post them here and other BB members will try and answer.

IMO:
1. Many people that are walking around healthy right now would choose not to have a vaccine.
2. Those same people lying in a hospital bed with few options to save their lives, WOULD take a therapeutic administered by nursing staff.

This is just something that makes reasonable common sense IMO. So it would follow in an ideal world, that if there was an endless supply of our therapeutic then the demand is satisfied by circumstance. It would sell itself as long as it can see to be the best therapeutic option.

My question are:

1. Who is going to get the drug?
2. Will they have to pay for it?
3. If the patient does not pay, who will pay for it? Will it be an organisation such as Asthma UK?

Clearly we all have many questions so that we can all arrive a reasonable understanding here. Hopefully as Manifesto said earlier, RM can clear these and many points up. For now if anybody can offer their insight I would appreciate a good debate - discussion.

GLA.

The main purpose of P£ is to demonstrate continued efficacy and also to show Lupizor is better than current treatments. That's the long and short of it.

We don't have a rampaty ramp CEO. We only get news that matters and although we have not been spoiled with RNS (cough TILS!) we may be getting more than we have been used to in the next few months. Lets hope.

Yes Asthma is a wicked disease that can take people from us in hours. Whilst inhaled interferon may well help people with compromised help conditions most of all it needs approval. This is the first significant step. Hopefully now we can register hundreds in our trials not just a handful.

City Trader,

SNG are wearing big boy pants now. With the SP at these levels only amazing news will move it forward dramatically. What everyone needs to understand is that amazing news does not come in one RNS. It takes several and I think this will be the first of many!

GLA

Well for what its worth VAL got the big FDA RNS they dreamed of. That was the problem really, it wasnt from the FDA, it was from a clinical trial but who needs facts! The words and facts written in the RNS seemed to have been misinterpreted by the masses of private investors. A rather modest and if I might say uninspiring result was transformed by many readers into something that Harry Potter himself might have been proud of; Arampiamus???

VAL201 was well tolerated, but not particularly effective. By increasing the dose will it still be efficacious? That is the question and it will require more money for another trial (sounds like SNG don't you think?).

All I wish for here is a good result that will allow Immupharma to take the next step along its journey. Nice and steady away. I think with Nolupus around to offer his observations and musings, our feet will be kept firmly on the ground where they should be.

Anyhow, the main thing I wanted to say was that the FDA approval if there ever was one for VAL is still pending. The next one that is due will be for DNL and it may arrive tomorrow - we shall see, but I certainly hope so as it would help me patchy portfolio. To be realistic, I think that will be delayed as well. So, Imm is not the only Pharma waiting on news from the FDA. More patience required me thinks.

I missed the DDDD pharma boat. Even when it retraced back to around a pound a couple of weeks back I didn't go for it. That was pretty much because I have so many different types of investment already. Imagine my horror when the SP walloped £1.70+ with absolute ease. It was then that I realised the potential of a great pharma company with a wonder drug.

So what's my point?
I have not missed the boat here :-) I recognised the potential and I am glad to be on board. My experience watching DDDD pharma from the side lines means I am not letting this slip through my greedy sticky fingers. This stock will drop only so the II and Investment Companies can load up, but as soon as that is done it will take off. It will pause for breath along the way more than once but this is heading for £1.70+ just like DDDD.

GLA and DYOR. If you know the science you will be best informed to make your own investment choices!

Marvellous!

A little light reading for any doubters about interferons and the science behind our therapeutic.

https://en.wikipedia.org/wiki/Interferon

Seems to back up what the good Dr has to say...

Hewhodares,

Maybe you would like to deconstruct the science? Not about SNG and its novel delivery method for the therapeutic. Maybe you could let us know exactly what is wrong with the appraisal of interferons and the purpose they serve in immune response?

Miggy,

Sooner rather than later would be fantastic from a clinical point of view. :-)

https://www.youtube.com/watch?v=wqDd7ixh184

Worth a watch if the derampers are getting to you :-)

I accept your point Sparkle. Preparedness is certainly a good sign :-)

It appears to me that the holders here have sticky hands and as long as we get through the results unscathed, we will live to fight another year. Hemo certainly are looking at the right kind of therapeutics and immune response. I would say they are not an obvious choice for an outstanding move upwards but they may well surprise us. This is the first stock that I bought into and it has not been unkind to me.

ATB.